MiNK Therapeutics, Inc. INKT

MiNK Therapeutics (INKT) released its Q2 2026 earnings call transcript covering financial results and business updates. Quarterly earnings data can shift near-term investor views and share price without altering long-term strategy.

MiNK Therapeutics, Inc. (INKT) issued a Q2 2026 earnings call summary covering financial results and operational updates. Earnings call summaries disclose quarterly results and guidance that can shift near-term stock sentiment and valuation.

MiNK Therapeutics' Q2 2026 earnings call highlighted early promise for AGENT-797. AGENT-797 early promise in earnings call signals moderately noticeable influence on MiNK's performance and positioning.

MiNK Therapeutics Q2 earnings call highlights financial results, operational updates and pipeline status for INKT. Q2 earnings call supplies financial and pipeline data that can shift near-term investor sentiment and valuation.

MiNK Therapeutics reported second quarter 2026 financial results and observations from its randomized Phase 2 trial of agenT-797 in acute lung injury. Quarterly financials and Phase 2 trial observations may shift near-term sentiment around pipeline progress without guaranteeing major trajectory changes.

MiNK Therapeutics dosed the first patient in a randomized Phase 2 trial of agenT-797 targeting acute lung injury and critical illness. Phase 2 trial initiation signals clinical pipeline progress for core asset agenT-797 without immediate revenue or approval impact.

MiNK Therapeutics reports new data on agenT-797 allo-iNKT cell therapy at ATS 2026 with simultaneous publication in Clinical Immunology Communications. New data presentation on lead therapy supports ongoing product development and may moderately shift investor views.

MiNK Therapeutics held its Q1 2026 earnings call covering quarterly financial results, operational updates, and forward outlook for the company's development programs. Quarterly earnings updates deliver financial and pipeline details that can shift near-term sentiment without fundamentally changing long-term company trajectory.

MiNK Therapeutics (INKT) released Q4 2025 earnings call transcript covering financial results, pipeline updates, and strategic outlook. Q4 earnings transcripts disclose financial metrics, clinical progress, and guidance that drive substantial shifts in investor sentiment and stock valuation.

MiNK Therapeutics, Inc. (INKT) reported first quarter 2026 financial results and advanced its iNKT cell therapy platform into randomized clinical validation. Advancing iNKT cell therapy to randomized clinical validation is a major milestone likely to significantly impact clinical progress, investor sentiment, and market performance.

MiNK Therapeutics reported Q1 2026 earnings highlights covering strategic advances in its pipeline and updated financial results including cash position and operating expenses. Earnings call details on strategic pipeline progress and finances are likely to produce moderate short-term shifts in investor sentiment without fundamentally redefining long-term trajectory.

MiNK Therapeutics Q1 earnings call highlights financial results, clinical pipeline progress including iNKT cell therapies, partnership updates, and outlook for upcoming trials and cash position. Q1 earnings highlights detail financials and pipeline advancements with moderate influence on investor sentiment and near-term trajectory.

MiNK Therapeutics, Inc. (INKT) and First Lviv Territorial Medical Union have initiated a randomized Phase 2 trial evaluating agenT-797, an invariant natural killer T cell therapy, in patients with acute lung injury and critical illness. Initiating a randomized Phase 2 trial advances MiNK's lead iNKT therapy into a critical efficacy-testing stage in high-unmet-need indications.

MiNK Therapeutics presented clinical evidence at ASGCT 2026 showing a single, off-the-shelf iNKT cell product drives context-dependent immune responses. Clinical data presentation on core iNKT cell therapy at major gene and cell therapy conference likely boosts investor sentiment and pipeline validation.

MiNK Therapeutics to report first quarter 2026 financial results and highlight platform progress across iNKT cell therapy programs. Financial results and iNKT cell therapy progress updates will moderately influence investor sentiment and company trajectory.

MiNK Therapeutics announced Phase II data demonstrating immune reprogramming and durable survival in patients with PD-1 refractory gastroesophageal cancer. Phase II success in PD-1 refractory gastroesophageal cancer validates MiNK's iNKT therapy platform and could spur partnerships, Phase III trials, and stock gains.

MiNK Therapeutics (INKT) and Memorial Sloan Kettering Cancer Center will present Phase II study results of agenT-797 in combination therapy for PD-1 refractory gastroesophageal cancer at the AACR Annual Meeting 2026. Phase II data presentation at AACR 2026 on agenT-797 combination could validate efficacy in refractory gastroesophageal cancer, significantly advancing INKT's oncology pipeline and market prospects.

Agenus announces Phase II study data of BOT+BAL combined with agent-797 in PD-1 refractory gastroesophageal cancer for presentation at AACR 2026. Upcoming Phase II data presentation of agenT-797 combo at AACR validates MiNK's lead asset in refractory cancer, likely driving significant investor sentiment and stock momentum.

MiNK Therapeutics to present new data at ASGCT 2026 highlighting context-dependent activity of iNKT cell therapy. Upcoming presentation of new iNKT cell therapy data at a major gene and cell therapy conference could moderately enhance MiNK Therapeutics' visibility and investor sentiment.

MiNK Therapeutics Inc. (INKT) highlighted strategic advances and financial updates during its Q4 2025 earnings call. Strategic advances in Q4 2025 earnings call signal major shifts in INKT's development pipeline and market positioning.

MiNK Therapeutics released Q4 earnings call highlights covering financial results, clinical pipeline progress, operational updates, and forward-looking guidance. Q4 earnings call highlights deliver key financial metrics, pipeline advancements, and strategic outlook that significantly shape investor sentiment and stock trajectory.

MiNK Therapeutics (INKT) reported Q4 and full-year 2025 financial results, with Phase 2 programs advancing supported by impactful non-dilutive funding momentum. Phase 2 program advancements and non-dilutive funding represent major strategic progress likely to boost INKT's clinical pipeline and market sentiment.

MiNK Therapeutics, Inc. (INKT) Q4 2025 earnings call summary covers financial results, clinical pipeline updates, and forward-looking guidance for the cell therapy developer. Q4 earnings call summary provides insights into financial performance and clinical progress with moderate potential to affect stock sentiment and trajectory.

MiNK Therapeutics, Inc. (INKT) will report fourth quarter and full year 2025 financial results and highlight platform expansion across iNKT cell therapy programs. Earnings report and platform expansion updates could moderately affect financial performance and investor sentiment.

MiNK Therapeutics announces collaboration with C-Further to advance PRAME-targeted iNKT cell therapy for pediatric cancers. Collaboration validates MiNK's iNKT platform in pediatric oncology, a strategic expansion that could significantly enhance pipeline value and investor sentiment.

C-Further unveils first therapeutic programmes dedicated to paediatric oncology. Unveiling inaugural paediatric oncology programmes marks a major strategic pipeline expansion for INKT in a high-unmet-need area.

MiNK Therapeutics, Inc. presented new data on its allo-iNKT cell therapy as a potential disease-modifying treatment for idiopathic pulmonary fibrosis at the Keystone Symposia. The findings suggest that this innovative approach could significantly impact the management of this challenging lung disease, highlighting the therapeutic potential of allo-iNKT cells in altering disease progression. The presentation of new data on a potential treatment for idiopathic pulmonary fibrosis could significantly influence MiNK Therapeutics' market position and investor sentiment.

Agenus reported its Q2 2025 earnings, highlighting key financial metrics and strategic initiatives. The company discussed advancements in its immunotherapy pipeline and ongoing collaborations aimed at enhancing its market position. Financial results showed fluctuations in revenue and expenses, reflecting the impact of research and development investments. The management provided insights into future growth prospects and market challenges, emphasizing a commitment to innovation and shareholder value. The earnings call reveals important financial updates and strategic directions that may moderately influence the company's performance.

MiNK Therapeutics, Inc. and the University of Wisconsin–Madison have announced the initiation of a Phase 1 clinical trial for their Allo-iNKT cell therapy, AgenT-797. This trial aims to evaluate the therapy's effectiveness in preventing graft-versus-host disease (GVHD) in patients undergoing hematopoietic stem cell transplantation. The collaboration seeks to leverage the unique properties of iNKT cells to improve patient outcomes in this challenging area of treatment. The Phase 1 clinical trial represents a significant strategic move that could enhance MiNK Therapeutics' product offerings and market position in the field of cell therapies.

MiNK Therapeutics, Inc. announced new data demonstrating that MiNK-215 exhibits strong anti-tumor activity in treatment-resistant solid tumors. The findings suggest that MiNK-215 could be a promising therapeutic option for patients with limited treatment alternatives, potentially enhancing the company's position in the oncology market. The data indicates significant therapeutic potential for MiNK-215, which could alter the company's trajectory and investor sentiment.